Roche's Ventana to Develop Companion Tests for Incyte, Starting with Phase II IDO1 Inhibitor | GenomeWeb

Roche Subsidiary Ventana Medical Systems and Incyte announced this week that the two companies have made an agreement under which Ventana will support Incyte's cancer drug development with companion diagnostic tests, beginning with a test for a compound in Incyte's IDO1 inhibitor program.

Incyte's Group Vice President Victor Sandor said in a statement that "with the advancement of INCB24360 into multiple Phase 2 studies, [the company's] first-in-class IDO1 inhibitor program was a logical place to begin to incorporate potential companion diagnostics."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.